

## Abridged Curriculum Vitae

**Full Name:** POPESCU MIRCEA IOACHIM

**Nationality :** ROMANIAN

**Academic Title:** Professor, PhD MD

**Present Position (including name and address of the institution):**

Head of Cardiology Clinic

Chief of Department

Emergency County Hospital of Oradea

**Starting Date in this Position:**

### Relevant Professional Qualifications (*Post Graduate Training*)

Qualification	Dates
Secondary in Cardiology: Heart Institute Cluj- Napoca under the direction of Prof. N. Stăncioiu and Associate R. Căpâlneanu	1989- 1991
Specialist in Cardiology at County Hospital Oradea	From 1992
Senior physician in Cardiology: Heart Institute from Cluj- Napoca	15 February 1997
MD Cardiologist at: County Hospital Oradea	From 1997
Competence in Echocardiography – Bucharest, Fundeni Hospital	1997
PhD: University of Medicine and Pharmacy " Julius Hatieganu", Cluj- Napoca, 2000;doctoral supervisor: Prof. Dumitru Zdrenghea, Thesis title: " The practice importance of angiotensin converting enzyme inhibitors in the treatment of heart failure. Comparative study with other drugs."	
Clinical internship training, echocardiographic, and angiographic Clinic " Heiling Hartkliniek" Eeklo, Belgium under the direction of Dr. SM H	
Postgraduate courses followed: 31 of which 16 international and 15 national.	
Taught graduate courses: 4	

### Relevant Experience/ Positions (*Responsibility/ Years*):

Experience	Dates
Specialist Public Health and Health Management	2003
Lecturer – Medical Clinic III, Faculty of Medicine and Pharmacy, Oradea	1998
Associate Professor- Medical Clinic III, Faculty of Medicine and Pharmacy, Oradea	2002
Chief of Medical Department III	2006- 2009
Chief of Cardiology Clinic	2009- present
Professor, Cardiology Clinic, Faculty of Medicine and Pharmacy, Oradea	2009
Chief of Prevention and Rehabilitation Working Group of Romanian Society of Cardiology	2014- 2017

**Other relevant information** (e.g. Publications, participation in International Conferences/Clinical trials):

	Dates
"Myocardial Ischaemia", Budapest	12-14 February 1998
"Diagnosis and Management of Heart Failure- Current status and future Developments", Timisoara	5-6 June 1998
"Unstable Angina, Risk Stratification and Management", Budapest	25-27 February 1999
"Ischaemic Heart Disease: State of the Art", Budapest	4-6 May 2000
"Endothelial dysfunction and cardiovascular disease", Rome, Italy	2004
"The 13 <sup>th</sup> International Workshop in Cardiovascular Disease", Dijon	2005
"Managing Cardiovascular Risk through Dual inhibition of Two Sources of Cholesterol", Barcelona	2006
"Accupril Global Speaker Training", Prague	2006
"International Advances in Cardiovascular Therapy, Prague	2006
"Training on good clinical practice (GCP) in clinical research", Timisoara	17-18 October
"International experts workshop on early treatment strategies for acute myocardial infarction", Dresda	2007
"The everyday challenge of prevention", The European Heart House	2007
"Cardiology and Vascular Medicine Update and Perspective", Rotterdam	2007
"Targeting Myocardial Ischaemia- Future opportunities for improved Outcomes", Vienna	2007
"The Growing Challenges in Cholesterol Management: Testing to New Standards for Inhibiting Cholesterol Absorption and Production", Lisbon	2008
PI: Project CNCSIS, 1593 "Evaluation of markers of subclinical atherosclerosis in young people with cardiovascular risk factors. Developing an optimal strategy of prevention of cardiovascular diseases"	2008-2012
PI: VASCO study, "Assesment of the antianginal efficacy and safety of trimetazidine MR 35mg compared to placebo in Patients with stable angina pectoris and 50 mg o.d atenolol as background therapy. A 12 weeks Multicenter, International, randomized, double blind, parallel group study"- Institut de Recherches Internationales Servier	2005-2009
PI: Study 057- "Evaluation of anti-angina efficacy and safety of oral administration of ivabradine compared to placebo on top of a background therapy with atenolol in patients with stable angina pectoris. A 4 month randomized double blind parallel group international multicenter study"- Institut de Recherches Internationales Servier	2006-2007
PI: Study "A phase III clinical trial comparing rivaroxaban tp warfarin in patients with non valvular atrial fibrillation"- Johnson and Johnson Pharmaceutical Research and Development	2006-2009
PI: the study "Evaluation of the anti-anginal efficacy and safety of oral administration of ivabradine compared to placebo on top of a background therapy with a calcium antagonist (amlodipine or nifedipine) in patients with stable angina pectoris: CL-16257-068-MDSPS-2008	2006-2009
PI: Study "The ATLAS ACS 2/TIMI 51, Trial (The second trial of Anti-Xa. Therapy to Sower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome)-Johnson and Jonson, Pharmaceutical Research and Development.	2008- 2010
PT: Study " Randomised, double blind, addition of hydrochlorotiazide in subjects with moderate to severe hypertension who do not reach target blood only fixed dose Olmesartan, medoxomil/ amlodipine combination of 40-10mg" CS8635-A-E303, MDS Pharma Services France SAS.	2009

APEX- Acute Medically III VTE Prevention with Extended Duration Betrixaban Trial. Protocol: APEX-11-019- Portola Pharmaceuticals, Augustresearch.	2012-2015
ATPCI study. The efficacy and safety of Trimetazidine in Patients with angina pectoris having been treated by percutaneous Coronary Intervention. Institut de Recherches Internationales Servier (I.R.I.S.). Protocol CL3-06790-010.	2013-2016
FOURIER study-A Double- blind, Randomized, Placebo- controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When AMG 145 is Used in Combination With Statin Therapy In Patients with Clinically Evident Cardiovascular Disease. Protocol 20110118.Amgen Inc	2013-2016
CAD ("Efficacy of Ranolazine in Patients with Coronary Artery Disease (CAD) - Protocol no. MEIN/10/Ran- Cad/003"). Phidea Group.	2014-2016
LCZ696D. A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patient (NYHA Class II-IV) with preserved ejection fraction. Protocol No. CLCZ696D2301. Novartis	2015-2018
Co-investigator: Beautiful study, "Effects of Ivabradine on Cardiovascular Events in Patients with stable coronary disease and left ventricular systolic artery dysfunction. A three year randomized double blind placebo-controlled Multicenter International Study"- Institut de Recherches Internationales Servier	2005-2007
Co-investigator: The study "The initial management of stable angina in Europe", from the Euro Heart Survey", published in the European Heart Journal, vol. 26, no. 10may 2005, pp. 1011-1022	2005
International congresses: 30	1998-2012
National congresses with international participation: 30	1998-2012
Papers communicated (oral or poster):26 from which 6 as the first author since the last promotion.	
Papers published in journals or volumes summarized in national scientific events and International (including international participation): 60 from which 16 as the first author since the last promotion.	
Papers published in full in magazines or scientific events of interest volumes national and international( with international participation): 58 of which 23 as a first author.	

Good Clinical Practice Training: GCP training "NIDA Clinical Trials Network" expires 13 Febr. 2017.

This abridged C.V. represents an accurate summary of my current C.V.



Signature of Investigator (if applicable)

Date: 05 FEB. 2016.